BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 27717137)

  • 1. Corrosion-Activated Chemotherapeutic Function of Nanoparticulate Platinum as a Cisplatin Resistance-Overcoming Prodrug with Limited Autophagy Induction.
    Cheng HJ; Wu TH; Chien CT; Tu HW; Cha TS; Lin SY
    Small; 2016 Nov; 12(44):6124-6133. PubMed ID: 27717137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An upconversion nanoplatform for simultaneous photodynamic therapy and Pt chemotherapy to combat cisplatin resistance.
    Ai F; Sun T; Xu Z; Wang Z; Kong W; To MW; Wang F; Zhu G
    Dalton Trans; 2016 Aug; 45(33):13052-60. PubMed ID: 27430044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fighting against drug-resistant tumors by the inhibition of γ-glutamyl transferase with supramolecular platinum prodrug nano-assemblies.
    Wang L; Liu Z; He S; He S; Wang Y
    J Mater Chem B; 2021 Jun; 9(22):4587-4595. PubMed ID: 34059856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multipronged Design of Light-Triggered Nanoparticles To Overcome Cisplatin Resistance for Efficient Ablation of Resistant Tumor.
    Li Y; Deng Y; Tian X; Ke H; Guo M; Zhu A; Yang T; Guo Z; Ge Z; Yang X; Chen H
    ACS Nano; 2015 Oct; 9(10):9626-37. PubMed ID: 26365698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
    Wang Z; Xu Z; Zhu G
    Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
    Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
    ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imidazole modified Pt(iv) prodrug-loaded multi-stage pH responsive nanoparticles to overcome cisplatin resistance.
    Kang X; Wang Y; Chen Z; Wu Y; Chen H; Yang X; Yu C
    Chem Commun (Camb); 2020 Sep; 56(76):11271-11274. PubMed ID: 32830841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
    Wang Z; Deng Z; Zhu G
    Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
    Yu C; Ding B; Zhang X; Deng X; Deng K; Cheng Z; Xing B; Jin D; Ma P; Lin J
    Biomaterials; 2018 Feb; 155():112-123. PubMed ID: 29175080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-Based Autophagic Gene and Cisplatin Co-delivery Systems Enable Improved Chemotherapy Resistance.
    Lin YX; Wang Y; An HW; Qi B; Wang J; Wang L; Shi J; Mei L; Wang H
    Nano Lett; 2019 May; 19(5):2968-2978. PubMed ID: 30924343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergic highly effective photothermal-chemotherapy with platinum prodrug linked melanin-like nanoparticles.
    Zhang C; Zhao X; Guo H
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):356-363. PubMed ID: 29607699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo.
    Luo K; Guo W; Yu Y; Xu S; Zhou M; Xiang K; Niu K; Zhu X; Zhu G; An Z; Yu Q; Gan Z
    J Control Release; 2020 Oct; 326():25-37. PubMed ID: 32531414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Platinum(II) agent induces bimodal death of apoptosis and autophagy against A549 cancer cell.
    Wang FY; Huang KB; Feng HW; Chen ZF; Liu YN; Liang H
    Free Radic Biol Med; 2018 Dec; 129():418-429. PubMed ID: 30266678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells.
    Cetraz M; Sen V; Schoch S; Streule K; Golubev V; Hartwig A; Köberle B
    Arch Toxicol; 2017 Feb; 91(2):785-797. PubMed ID: 27307157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in vivo highly antitumor-active tetrazolato-bridged dinuclear platinum(II) complex largely circumvents in vitro cisplatin resistance: two linkage isomers yield the same product upon reaction with 9-ethylguanine but exhibit different cytotoxic profiles.
    Uemura M; Suzuki T; Nishio K; Chikuma M; Komeda S
    Metallomics; 2012 Jul; 4(7):686-92. PubMed ID: 22473092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
    To KK; Tong WS; Fu LW
    Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles.
    Kalayda GV; Jansen BA; Wielaard P; Tanke HJ; Reedijk J
    J Biol Inorg Chem; 2005 May; 10(3):305-15. PubMed ID: 15824924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
    Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
    J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graphene oxide sensitizes cancer cells to chemotherapeutics by inducing early autophagy events, promoting nuclear trafficking and necrosis.
    Lin KC; Lin MW; Hsu MN; Yu-Chen G; Chao YC; Tuan HY; Chiang CS; Hu YC
    Theranostics; 2018; 8(9):2477-2487. PubMed ID: 29721093
    [No Abstract]   [Full Text] [Related]  

  • 20. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
    Chen F; Qin X; Xu G; Gou S; Jin X
    Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.